Wednesday, April 24, 2013 12:24:40 PM
New investors to Elite Pharmaceuticals should read this latest
Seeking Alfa artical Couch posted.
http://seekingalpha.com/user/9750161/instablog
Excellent read that goes into depth about the company and its potential with the Abuse Resistant Technology (ART).
The company is also making strides towards revenue break even cash flow positive which will also be a huge event. First time EVER in the companies history. Should happen this quarter or the next. Contributions from manufactured products at the facility
will go a long way toward helping to pay the bills.
More drugs to come to production in their pipeline too.
Both phentermine capsule doses should keep everyone pretty busy
for the time being. If those of you are wondering why the hold up with Naltrexone one only has to think back to the "delay" with phentermine capsules. Limited staff more than a handful of products expanding studies (stability) along with quality control testing USP guidelines FDA approved for each lot produced. This equals a whole lot of work involved. Many of the current staff may just about be living at the facility.
The latest $10 million financing from Lincoln Park should be all they need to get the Phase III trials rolling along for their ART product(s). Jerry said that they are further along than people think. When Elite can bring an ART product(s) to fruition that is when shareholders are likely to see the shareprice begin to rise and Wall Street begin to take this company seriously.
Check out the history of Elite Pharmaceuticals as posted by Couch.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87180690
Another excellent read.
This is a longterm investment. It will have its ups and downs.
Patience is the key here.
Seeking Alfa artical Couch posted.
http://seekingalpha.com/user/9750161/instablog
Excellent read that goes into depth about the company and its potential with the Abuse Resistant Technology (ART).
The company is also making strides towards revenue break even cash flow positive which will also be a huge event. First time EVER in the companies history. Should happen this quarter or the next. Contributions from manufactured products at the facility
will go a long way toward helping to pay the bills.
More drugs to come to production in their pipeline too.
Both phentermine capsule doses should keep everyone pretty busy
for the time being. If those of you are wondering why the hold up with Naltrexone one only has to think back to the "delay" with phentermine capsules. Limited staff more than a handful of products expanding studies (stability) along with quality control testing USP guidelines FDA approved for each lot produced. This equals a whole lot of work involved. Many of the current staff may just about be living at the facility.
The latest $10 million financing from Lincoln Park should be all they need to get the Phase III trials rolling along for their ART product(s). Jerry said that they are further along than people think. When Elite can bring an ART product(s) to fruition that is when shareholders are likely to see the shareprice begin to rise and Wall Street begin to take this company seriously.
Check out the history of Elite Pharmaceuticals as posted by Couch.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=87180690
Another excellent read.
This is a longterm investment. It will have its ups and downs.
Patience is the key here.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
